Contact Us | Home
Toll Free No. for USA/Canada:   1-866-279-8368
| Advance Search
Currency:  $
Discounted Reports
Energy & Resources
FMCG & Retailing
Pharmaceuticals and Healthcare

Novartis, 2013 Outlook revised but below expectations

Enquire | Email | Print

Published Date: Jul, 2013
Format: PDF
No of Pages: 3
Select pricing :
Change Currency: EURO | $ USD | GBP
Buy through us and save. We do not add any Tax / Duty including VAT,GST
  • Abstract
  • Table of Contents

Novartis reported strong 2Q-2013 financial results due to the absence of Diovan generics in the US. For the same reason, Novartis has revised its earning guidance for the full year 2013. It now expects group net sales to grow at a low-single digit and the group core operating income to decline at a low-single digit rate. We see the revision in guidance as inadequate and not reflective of the gains due to delayed Diovan generic entry. Despite the higher than expected sales base in 2013, the company still retains its guidance for 2014 and 2015 (mid single digit growth).

Related Reports:  


Custom Research
If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice. Please visit Custom Research page to make an enquiry.


Top Go to top of the page

product id: 216371, price: INR 5481, MP Advisors

International Travel Grant for Members of
MANLIBNET (Management Libraries Network)
We accept
Phone: +91.22.27810772, 27810773
Hours: Mon to Sat 8:00 AM to 8:00 PM IST
Call USA/Canada 1-866-279-8368
About Trust Online